Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report

Abstract

type I and type II receptors). Nevertheless, the decision to initiate a dupilumab treatment in transplant recipients must be made interdisciplinary, carefully considering the individual risk-benefit prospects together with the patient. Larger series of patients with longer follow-up periods are required to estimate the risk-benefit ratio of dupilumab treatment in transplant recipients.

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

“…1). Full texts of 571 records were assessed, of which 25 met our eligibility criteria 10–34 . Eleven studies were conducted in Europe, 10 in the United States, 2 studies in Asia, 1 in Australia, and 1 study in Mexico.…”

“…Three studies examined treatment with oral corticosteroids, 19,27,32 with one of these studies also treating with 11 months of azathioprine after 1 month of oral prednisone 27 . Two studies examined treatment with dupilumab, 25,29 with one of these studies (Bosma et al 25 ) reporting a patient with renal insufficiency and liver function abnormalities, who was treated with dupilumab 25 …”

“…19,25,27,29,32 Three studies examined treatment with oral corticosteroids, 19,27,32 with one of these studies also treating with 11 months of azathioprine after 1 month of oral prednisone. 27 Two studies examined treatment with dupilumab, 25,29 with one of these studies (Bosma et al 25 ) reporting a patient with renal insufficiency and liver function abnormalities, who was treated with dupilumab. 25 In addition to the study by Bosma et al, 25 5 additional studies (2 case reports, 3 cohorts) reported a total of 13 participants with renal disease, including hydronephrosis, renal insufficiency, and endstage renal disease.…”

Practical Management of Patients with Atopic Dermatitis on Dupilumab

“…All cases reported significant effectiveness and safety for as long as 2 years with no new safety issues or concerning infections reported [ 64 ]. Notably, conjunctivitis was observed in two patients following dupilumab initiation and required artificial tears, periocular tacrolimus, and/or steroid drops [ 64 , 65 ].…”

“…There are several case reports of dupilumab use in patients experiencing AD following solid organ transplants including heart and liver [62][63][64][65]. All cases reported significant effectiveness and safety for as long as 2 years with no new safety issues or concerning infections reported [64].…”